Usefulness of a New Immunoradiometric Assay of HCV Core Antigen to Predict Virological Response during PEG-IFN/RBV Combination Therapy for Chronic Hepatitis with High Viral Load of Serum HCV RNA Genotype 1b
Authors:
- Soo Ryang KimSKSoo Ryang Kim
- Ke Ih KimKKKe Ih Kim
- Miyuki TaniguchiMTMiyuki Taniguchi
- Susumu ImotoSISusumu Imoto
- Keiji MitaKMKeiji Mita
- Hak HottaHHHak Hotta
- Ikuo ShoujiISIkuo Shouji
- Ahmed El-ShamyAEAhmed El-Shamy
- Norifumi KawadaNKNorifumi Kawada
- Masatoshi KudoMasatoshi Kudo
- Yoshitake HayashiYHYoshitake Hayashi
- 1 June 2008
- journal article
- treatment of-chronic-hepatitis-c
- Published by S. Karger AG in Intervirology
- Vol. 51 (Suppl. 1) , 70-75
Abstract
We investigated the clinical usefulness of a new immunoradiometric (IRM) assay of hepatitis C virus (HCV) core antigen in predicting virological response during pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy for chronic hepatitis with high viral loads of serum HCV RNA genotype 1b. Thirty-nine patients received a regimen of PEG-IFNα-2b (1.5 µg/kg/week s.c.) in combination with RBV (600–1,000 mg/day). Of the 39 patients, 18 (46.2%) achieved sustained virological response (SVR), 11 (28.2%) attained partial response (PR) and 10 (25.6%) showed no response (NR). Four weeks after the start of therapy, 1- and 2-log reductions in the amount of HCV core antigen were observed in 20 (2/10) and 0% (0/10) showing NR, 91 (10/11) and 63.6% (7/11) with PRs, and 88.9 (16/18) and 55.6% (10/18) of patients with SVR, respectively. The 1- and 2-log reductions 4 weeks after the start of therapy were not a definingcondition for PR and SVR. The amount of HCV core antigen was significantly different between SVR and PR patients on days 1 and 7, and between patients with NR and SVR at all points of time. In conclusion, this new IRM assay is useful in predicting virological response during PEG-IFN/RBV therapy.Keywords
This publication has 1 reference indexed in Scilit:
- Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core AntigenJournal of Clinical Microbiology, 1999